InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
0.00%
)
US TECH 100
19,862.80
(
0.08%
)
Dow Jones
39,375.87
(
0.00%
)
Brent Oil
85.91
(
-0.69%
)
Bitcoin
57,179.15
(
2.39%
)
Post# of 252508
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: ghmm post# 221717

Monday, 10/29/2018 4:59:08 PM

Monday, October 29, 2018 4:59:08 PM

Post# of 252508
Please keep in mind I'm talking out of my butt here since I haven't done any research yet, but one might expect the incidence of anti-dMAb antibodies to be lower than exogenously administered antibodies because all the normal post-translational modifications are going to be in place and they are thus less likely to elicit an immune response.

Can someone help me understand, though, what the point of producing therapeutic proteins and antibodies endogenously is? Why bother, especially for therapeutic proteins?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up